Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
BMC Med Genomics. 2021 Jan 18;14(1):20. doi: 10.1186/s12920-020-00846-2.
To make the right treatment decisions about colorectal cancer (CRC) patients reliable predictive and prognostic data are needed. However, in many cases this data is not enough. Some studies suggest that LRIG1 gene (leucine-rich repeats and immunoglobulin-like domains1) has prognostic implications in different kinds of cancers.
One hundred and two patients with colorectal cancer were retrospectively analyzed for LRIG1 expression at both mRNA and protein levels. SYBR Green Real-Time RT-PCR technique was used for mRNA expression analyses and Glyceraldehyde-3-Phosphate Dehydrogenase gene (GAPDH) was considered as a reference gene for data normalization. LRIG1 protein expression was analyzed using Immunohistochemistry. Additionally, appropriate statistic analyses were used to assess the expression of LRIG1 in test and control groups. The prognostic significance of LRIG1 expression was analyzed using the univariate and multivariate analyses.
The data revealed that the expression of LRIG1 in both mRNA and protein levels was down regulated in colorectal tumor tissues (P < 0.01) but is not clinically relevant prognostic indicator in CRC.
Therefore, it is suggested that LRIG1 expression analyses may not be considered as an important issue when making informed and individualized clinical decisions regarding the management of colorectal cancer patients.
为了对结直肠癌(CRC)患者做出正确的治疗决策,需要可靠的预测和预后数据。然而,在许多情况下,这些数据并不足够。一些研究表明,LRIG1 基因(富含亮氨酸重复和免疫球蛋白样结构域 1)在不同类型的癌症中具有预后意义。
回顾性分析了 102 例结直肠癌患者的 LRIG1 在 mRNA 和蛋白水平上的表达。使用 SYBR Green Real-Time RT-PCR 技术进行 mRNA 表达分析,甘油醛-3-磷酸脱氢酶基因(GAPDH)被认为是数据归一化的参考基因。使用免疫组织化学分析 LRIG1 蛋白表达。此外,还使用适当的统计分析方法评估了 LRIG1 在实验组和对照组中的表达。使用单变量和多变量分析评估了 LRIG1 表达的预后意义。
数据显示,LRIG1 在 mRNA 和蛋白水平的表达在结直肠肿瘤组织中下调(P<0.01),但在 CRC 中不是临床相关的预后指标。
因此,建议在为结直肠癌患者的管理做出明智和个体化的临床决策时,LRIG1 表达分析可能不是一个重要问题。